The Myeloma Beacon » Atiprimod (azaspirane, SK&F106615)

Atiprimod (azaspirane, SK&F106615)

By: Admin; Published: October 15, 2008 @ 8:00 am | Comments Disabled

Brand Name:	Atiprimod
Generic Name:	azaspirane
Code Name:	SK&F106615
Company:	Callisto Pharmaceuticals
FDA Clinical Phase:	1/2

Description:

Atiprimod is a type of signal transduction inhibitor. It is being studied in the treatment of certain multiple myelomas and other advanced cancers. Atiprimod may block the growth of tumors and the growth of new blood vessels that tumors need to grow.

Clinical Trials:
For a list of clinical trials studying Atiprimod for the treatment of multiple myeloma, see ClinicalTrials.gov ^[1].

Source: NCI Cancer Glossary, Atiprimod, http://www.cancer.gov/templates/db_alpha.aspx?searchTxt=Atiprimod ^[2] (as of November 14, 2009)

Article printed from The Myeloma Beacon: https://myelomabeacon.org

URL to article: https://myelomabeacon.org/resources/2008/10/15/atiprimod/

URLs in this post:

[1] ClinicalTrials.gov: http://www.clinicaltrial.gov/ct2/results?term=&recr=&rslt=&type=&cond=multiple+myeloma&intr=Atiprimod&outc=&lead=&spons=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=

[2] http://www.cancer.gov/templates/db_alpha.aspx?searchTxt=Atiprimod: http://www.cancer.gov/templates/db_alpha.aspx?searchTxt=Atiprimod

Click here to print.